NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 200 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 200 is a fixed-dose oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting aromatic amino acid decarboxylation, allowing more levodopa to reach the brain and prolonging its therapeutic effect. The entacapone component extends levodopa duration by inhibiting catechol-O-methyltransferase (COMT).
$0.151MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Medicare spending signals defensive positioning; expect focus on cost management and retention programs rather than expansion.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 200 offers experience in mature product lifecycle management, payer negotiations, and competitive positioning in a crowded neurology market. Career growth is constrained by LOE proximity; roles focus on retention, cost containment, and commercial excellence rather than expansion or innovation.
Brand Manager
Worked on STALEVO 200 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.